ArticleArchives of Razi Institute2025
X-ray Investigation of the Aging Process of Aluminum Hydroxide Adjuvant in Protein-Based Vaccine Formulations Over a Short Period.
Article in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nearly a century has passed since Glenny and colleagues introduced aluminum-based adjuvants. Over this extensive period, billions of doses of human and veterinary vaccines incorporating these adjuvants have been produced, ensuring both human health and food security. Aluminum-based adjuvants have played a pivotal role during epidemics, allowing scientists to accelerate vaccine development and save lives. Continuous research conducted by institutions worldwide has substantiated the safety and efficacy of aluminum-based adjuvants, establishing them as the gold standard. Consequently, any new adjuvant must be benchmarked against aluminum-based adjuvants and demonstrate substantial advantages in order to gain regulatory approval. This study aims to investigate the short-term structural and physicochemical changes in aluminum hydroxide in protein-based formulations under thermal treatments at 100°C for 24, 48, and 72 hours. These periods were designed to simulate the aging process that occurs during the storage of adjuvants at room temperature. Specifically, the research examines changes in the physicochemical properties of the adjuvant, including pH fluctuations during these thermal treatments, alterations in the sterilization process, protein adsorption capacity for each sample, particle size distribution, and X-ray diffraction (XRD) patterns. These findings not only enhance our understanding of adjuvant stability in vaccine formulations but also provide valuable insights into determining their optimal shelf life and performance. The study demonstrates that the best storage conditions for the adjuvant, with minimal impact from the aging process, are a low pH (pH=5) and higher ionic strength. It was also confirmed that innovative measures, such as reducing the sterilization cycle, stirring the samples after sterilization, and rapidly cooling them afterward, can prevent crystal growth and even produce smaller particle sizes with higher adjuvanticity. This is significant, as previous studies have reported a decline in adjuvanticity following sterilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.